Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
payday advance no credit check
Popular Articles
Benefits Of Grapefruit

Most, But Not All, Canadians With Chronic Conditions Get Clinically Recommended Tests
Most Canadians with chronic conditions have a regular place of care, but there are some reported gaps in the management of their conditions according to a new study released today by the Canadian Institute for Health Information (CIHI). The study, Experiences With Primary Health Care in Canada, measures access to and quality of care from a patient perspective across Canada"s 10 provinces. The study is based on the responses of more than 11,000 people age 18 and older to Statistics Canada"s 2008 Canadian Survey of Experiences With Primary Health Care, which was jointly funded by CIHI and the Health Council of Canada.
generic viagra online
Insurers Offer Reform Concessions, But Balk At Small Business Demands
"Employer-provided medical insurance remains the bedrock of the nation"s health care system. And yet, while most big employers still provide health benefits, soaring premiums have meant many small businesses can no longer afford to cover their workers," the New York Times reports. Some are concerned that many such businesses, those with fewer than 100 workers and which employ 40 percent of the labor force, will be left out of the health reform plan incubating in Congress. While insurers have offered key concessions to make it easier for individuals to buy insurance, saying they"ll "sell policies even to people with pre-existing medical conditions, and to stop basing prices on how healthy or sick someone is," the companies appear unwilling to give small employers the same break.
News of the day
Managing Incontinence After A Stroke - May Is Stroke Awareness Month
Approximately 800,000 people suffer a stroke in the United States each year, nearly three-quarters of which occur in people over 65 years old. On average, someone in the U.S. suffers a stroke every 40 seconds.
Cardiovascular

Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease

Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of a Phase 3 trial of the investigational drug dimebon (latrepirdine) in patients with Huntington disease. The international safety and efficacy trial, known as HORIZON, is designed to evaluate the potential benefits of dimebon on cognition (thinking and memory) in patients with Huntington disease. The companies also announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to dimebon for the treatment of Huntington disease. "Based on the promising results of our Phase 2 trial of dimebon in Huntington disease, we are pleased to advance dimebon into late-stage clinical development," said Lynn Seely, M.D., chief medical officer for Medivation. "Huntington disease is a fatal genetic disease for which no medications are currently approved by the FDA to treat the cognitive impairment associated with the condition." Orphan status is granted by the FDA to promote the development of products that demonstrate promise for the treatment of rare diseases affecting fewer than 200,000 Americans annually, such as Huntington disease, which affects 30,000 individuals in the United States, with another 150,000 at risk. Orphan drug designation entitles Pfizer and Medivation to a seven-year period of marketing exclusivity in the United States for dimebon if it is approved by the FDA for the treatment of Huntington disease. It also enables the companies to apply for research funding, tax credits for certain research expenses, and a waiver from the FDA"s application user fee. Latrepirdine is the proposed generic (nonproprietary) name for dimebon. Design of the HORIZON Study The double-blind, placebo-controlled Phase 3 trial will enroll approximately 350 patients with Huntington disease at approximately 50 sites in North America, Europe and Australia. Patients will be randomized to receive either dimebon (latrepirdine) 20 mg three times daily or placebo for six months. The primary endpoints of the trial are the Mini Mental State Examination (MMSE), which measures cognition, and the Clinician"s Interview-Based Impression of Change, plus caregiver input (CIBIC-plus), which measures global function. The trial will include only patients who have cognitive impairment, as subjectively assessed by an investigator and objectively by MMSE score. Secondary endpoints include the Neuropsychiatric Inventory (NPI), which measures behavior; the Alzheimer"s Disease Cooperative Study Activities of Daily Living (ADCS-ADL), which measures self-care and daily function; and the Unified Huntington Disease Rating Scale (UHDRS"99) Total Motor Score, which measures motor impairment; and safety. The trial is being conducted in collaboration with the Huntington Study Group (HSG) and the European Huntington"s Disease Network (EHDN). The HSG is a non-profit group of experienced clinical trial investigators from medical centers in the United States and abroad dedicated to clinical research of Huntington disease. The EHDN is a non-profit network of professionals providing an infrastructure for large scale Huntington disease clinical trials throughout Europe. About Dimebon Dimebon (latrepirdine) is an investigational drug in Phase 3 development for the treatment of Alzheimer"s disease (AD) and Huntington disease (HD). In preclinical studies, dimebon has been shown to protect brain cells from damage and enhance brain cell survival, potentially by stabilizing and improving mitochondrial function. The dimebon mechanism is distinct from currently available AD and HD medications. About Huntington Disease Huntington disease is a rare, neurodegenerative disease that is caused by the death of specific brain cells. The genetic disorder is characterized by the gradual development of involuntary muscle movements, cognitive impairment and severe behavioral disturbances. No medications are currently approved to treat the cognitive impairment (thinking and memory) of Huntington disease. About the Pfizer/Medivation Dimebon Collaboration Medivation and Pfizer have a global collaboration to develop and commercialize dimebon for the treatment of Alzheimer"s disease and Huntington disease. Under the terms of the agreement, the companies are working in partnership to seek FDA approval for dimebon and bring it to market in the United States. In addition, following FDA approval, Medivation will co-promote dimebon to specialty physicians in the U.S. Pfizer has responsibility for development, regulatory and commercialization outside of the U.S. PFIZER DISCLOSURE NOTICE: The information contained in this release is as of July 30, 2009. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about certain potential indications for dimebon, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any new drug applications that may be filed for such indications as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of any such indications; and competitive developments. A further list and description of risks and uncertainties can be found in Pfizer"s Annual Report on Form 10-K for the fiscal year ended December 31, 2008, and in its reports on Form 10-Q and Form 8-K. MEDIVATION DISCLOSURE NOTICE: This press release contains forward-looking statements, including statements regarding potential clinical indications for dimebon, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation"s actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation"s clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation"s clinical trials, partnering of Medivation"s product candidates, manufacturing of Medivation"s product candidates, competition with Medivation"s product candidates should they receive marketing approval, the adequacy of Medivation"s financial res, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation"s filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ended March 31, 2009 filed on May 11, 2009, with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release. Pfizer


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009